 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- || vorolanib (EYP-1901) / EyePoint Pharma, Fumena (vorolanib) / Tyrogenex, Betta Pharma
P1 data, Journal: Phase I DAVIO Trial: EYP-1901 Bioerodible, Sustained-Delivery Vorolanib Insert in Patients With Wet Age-Related Macular Degeneration. (Pubmed Central) - Jun 17, 2024
P1
These preliminary data support ongoing phase II and planned phase III trials to assess efficacy and safety. The author(s) have no proprietary or commercial interest in any materials discussed in this article.
- || Inlyta (axitinib) / Pfizer, vorolanib (EYP-1901) / EyePoint Pharma, Fumena (vorolanib) / Tyrogenex, Betta Pharma
Clinical, Journal: Vorolanib, sunitinib, and axitinib: A comparative study of vascular endothelial growth factor receptor inhibitors and their anti-angiogenic effects. (Pubmed Central) - Jun 4, 2024
Of the three TKIs, only axitinib potently inhibited TIE2 which is an undesired trait as TIE2 is essential for vascular stability. The findings support the use of vorolanib for therapeutic inhibition of angiogenesis observed in DR, DME, and wAMD.
- || vorolanib (EYP-1901) / EyePoint Pharma
New P2 trial: VERONA: Study of EYP-1901 in Patients With Diabetic Macular Edema (DME) (clinicaltrials.gov) - Oct 25, 2023
P2, N=25, Not yet recruiting, Sponsor: EyePoint Pharmaceuticals, Inc.
- | vorolanib (EYP-1901) / EyePoint Pharma
Trial completion date: DAVIO2: Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (clinicaltrials.gov) - May 10, 2023
P2, N=160, Active, not recruiting, Sponsor: EyePoint Pharmaceuticals, Inc.
The findings support the use of vorolanib for therapeutic inhibition of angiogenesis observed in DR, DME, and wAMD. Trial completion date: Dec 2023 --> Apr 2024
- || vorolanib (EYP-1901) / EyePoint Pharma
Enrollment closed: DAVIO2: Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (clinicaltrials.gov) - Mar 29, 2023
P2, N=160, Active, not recruiting, Sponsor: EyePoint Pharmaceuticals, Inc.
Trial completion date: Dec 2023 --> Apr 2024 Recruiting --> Active, not recruiting
- ||| vorolanib (EYP-1901) / EyePoint Pharma
Enrollment open: Study of EYP-1901 in Patients With Nonproliferative Diabetic Retinopathy (NPDR) (clinicaltrials.gov) - Feb 15, 2023
P2, N=105, Recruiting, Sponsor: EyePoint Pharmaceuticals, Inc.
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- vorolanib (EYP-1901) / EyePoint Pharma, vorolanib (X-82) / Tyrogenex
The DAVIO Trial: A Phase 1, Open-Label, Dose-Escalation Study of EYP-1901 (Vorolanib) demonstrating reduced Wet Age-Related Macular Degeneration Treatment Burden with Sustained Tyrosine Kinase Inhibitor Therapy. (Fontainebleau - Miami, FL) - Jan 13, 2023 - Abstract #Macula2023Macula_37;
More than half the eyes treated with EYP-1901 demonstrated OCT control of nAMD for 6 months or more after 1 treatment. EYP-1901 achieves sustained delivery of Vorolanib and a large phase 2 clinical trial is in development.
- ||| vorolanib (EYP-1901) / EyePoint Pharma
Enrollment open: DAVIO2: Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (clinicaltrials.gov) - Aug 22, 2022
P2, N=150, Recruiting, Sponsor: EyePoint Pharmaceuticals, Inc.
EYP-1901 achieves sustained delivery of Vorolanib and a large phase 2 clinical trial is in development. Not yet recruiting --> Recruiting
- vorolanib (EYP-1901) / EyePoint Pharma
EYP-1901: An Open-Label, Dose-Escalation Study Demonstrating Reduced Wet AMD Treatment Burden With Sustained TKI Inhibition () - Aug 8, 2022 - Abstract #AAO2022AAO_1422;
EYP-1901 had a favorable safety profile in the doses tested and controlled wAMD for 6 months or more in many eyes. This is an on-going 12-month study.
- || vorolanib (EYP-1901) / EyePoint Pharma
Trial completion, Enrollment change: First in Human Study to Evaluate the Safety and Tolerability of EYP-1901 in Patients With Wet Age Related Macular Degeneration (wAMD) (clinicaltrials.gov) - Jul 26, 2022
P1, N=17, Completed, Sponsor: EyePoint Pharmaceuticals, Inc.
This is an on-going 12-month study. Active, not recruiting --> Completed | N=13 --> 17
- vorolanib (EYP-1901) / EyePoint Pharma, vorolanib (X-82) / Tyrogenex
12-Month Results of EYP-1901 Vorolanib in Late a Bioerodible Durasert Insert for nAMD: The DAVIO Trial () - Jul 18, 2022 - Abstract #ASRS2022ASRS_168;
- ||| vorolanib (EYP-1901) / EyePoint Pharma
📈Reserve your virtual seat for #InvestorDay! @EyePointCEO, COO @DrJayDuker & CFO George Elston, will join #RetinalDisease experts, Drs. Carl Regillio & Charles Wykoff [@TXRetinaSurgeon] to discuss Durasert®, our sustained-delivery platform, & lead asset, #EYP1901. $EYPT (Twitter) - Jul 11, 2022
- |||| vorolanib (EYP-1901) / EyePoint Pharma
New P2 trial: Study of EYP-1901 in Patients With Nonproliferative Diabetic Retinopathy (NPDR) (clinicaltrials.gov) - May 20, 2022
P2, N=105, Not yet recruiting, Sponsor: EyePoint Pharmaceuticals, Inc.
- |||| vorolanib (EYP-1901) / EyePoint Pharma
New P2 trial: DAVIO2: Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (clinicaltrials.gov) - May 18, 2022
P2, N=150, Not yet recruiting, Sponsor: EyePoint Pharmaceuticals, Inc.
- vorolanib (EYP-1901) / EyePoint Pharma
Results Of a Phase 1 Dose Escalation Open Label Trial Of EYP-1901 in Previously Treated Wet AMD Patients (Morial Convention Center; THE GREAT HALL) - Oct 20, 2021 - Abstract #AAO2021AAO_465;
- || vorolanib (EYP-1901) / EyePoint Pharma
Enrollment closed: First in Human Study to Evaluate the Safety and Tolerability of EYP-1901 in Patients With Wet Age Related Macular Degeneration (wAMD) (clinicaltrials.gov) - May 26, 2021
P1, N=13, Active, not recruiting, Sponsor: EyePoint Pharmaceuticals, Inc.
Active, not recruiting --> Completed | N=13 --> 17 Recruiting --> Active, not recruiting
- || vorolanib (EYP-1901) / EyePoint Pharma
New P1 trial: First in Human Study to Evaluate the Safety and Tolerability of EYP-1901 in Patients With Wet Age Related Macular Degeneration (wAMD) (clinicaltrials.gov) - Feb 9, 2021
P1, N=13, Recruiting, Sponsor: EyePoint